^
    Back
    Association details:
    Biomarker:EZH2 rs2302427C>G
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Arch Med Res
    Title:

    EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker

    Published date:
    07/10/2023
    Excerpt:
    The genetic polymorphism analysis revealed two SNPs (rs.2302427C>G and rs.6950683T>C) of the three studied SNPs of the EZH2 gene have a protective role in all three genetic models....Three significant findings of the SNP rs.2302427C>G (Asp193His) i.e., protective role against breast cancer, survival advantage in ER+/tamoxifen treated breast cancer patients, and decreased expression due to the presence of mutant GG genotype, suggests considering it as an important prognostic biomarker for a good survival outcome of breast cancer patients treated with ER+/tamoxifen.
    DOI:
    10.1016/j.arcmed.2023.102852